Levosulpiride for diabetic eye swelling and retinopathy
Part of Brain & nervous system, Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This Phase 2 study tests whether levosulpiride can improve changes in the retina in people with diabetic retinopathy and diabetic macular edema (eye swelling that can affect vision). It may help by targeting chemicals in the body that could affect eye tissue and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 to 69 years old
- You have diabetic retinopathy and diabetic macular edema, and the eye doctor labels it mild to moderate (or proliferative retinopathy needing vitrectomy)
- You have not had certain recent or past eye treatments (eye surgery, laser treatment, or anti-angiogenic injections within the last 6 months)
- Your eyes do not have major problems like a retinal detachment, blocked vision from dense cloudiness, or very severe nearsightedness
- Your kidney function is in a certain range (milder for most groups, lower range allowed if you are having vitrectomy)
- You can take levosulpiride safely (no conditions like Parkinson’s disease, epilepsy, certain hormone-related cancers, alcohol misuse, or low potassium)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests a gene therapy injection into the eye to treat diabetic retinopathy (eye damage from diabetes) before it progresses. The goal is to slow or prevent vision loss and potentially delay the need for laser treatment or other injections.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.